Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercial expertise, developing ultra-long-acting antibodies for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis.
The company was founded in 2024.
Windward Bio is headquartered in Basel, Switzerland, with operations in the United States.
Windward Bio’s fiscal year ends on December 31.
Computershare Trust Company, N.A.
Ernst & Young
Cooley LLP, Niederer Kraft Frey AG
Windward Bio’s SEC filings can be viewed here.
You can email queries to the Windward Bio Investor Relations team by contacting investors@windwardbio.com.